Allogeneic, Umbilical Cord Blood-derived, Dual-targeting BCMA/CD19 CAR-T Therapy (Ucello)

N/A

Report date: 2025/12/04 09:39:20

Base Information

Drug NameAllogeneic, Umbilical Cord Blood-derived, Dual-targeting BCMA/CD19 CAR-T Therapy (Ucello)
Drug Alias NameUCB-derived, Dual-targeting BCMA/CD19 CAR-T (Ucello)allogeneic cord blood-derived, dual-targeting CD19/BCMA CAR-T cells (Ucello)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19Anti-BCMA
TargetsB-lymphocyte antigen CD19B-cell maturation protein
Therapy Area/IndicationsLupus Erythematosus, SystemicMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesUcello Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesUcello Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A